Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
School of Public Health, Qingdao University, Qingdao, China.
Drug Deliv. 2021 Dec;28(1):2329-2347. doi: 10.1080/10717544.2021.1995081.
In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expression of related genes also directly or indirectly affects tumor metabolism, metastasis, invasion, and apoptosis. There has been much research on targeted drug delivery systems designed for abnormal glucose and lipid metabolism due to their accuracy and efficiency when used for tumor therapy. In addition, gene mutations have become an important factor in tumorigenesis. For this reason, gene therapy consisting of drugs designed for certain specifically expressed genes have been transfected into target cells to express or silence the corresponding proteins. Targeted gene drug vectors that achieve their corresponding therapeutic purposes are also rapidly developing. The genes related to glucose and lipid metabolism are considered as the target, and a corresponding gene drug carrier is constructed to influence and interfere with the expression of related genes, so as to block the tumorigenesis process and inhibit tumor growth. Designing drugs that target genes related to glucose and lipid metabolism within tumors is considered to be a promising strategy for the treatment of tumor diseases. This article summarizes the chemical drugs/gene drug delivery systems and the corresponding methods used in recent years for the treatment of abnormal glucose and lipid metabolism of tumors, and provides a theoretical basis for the development of glucolipid metabolism related therapeutic methods.
近年来，各种类型肿瘤的发病率逐渐升高，并且发现异常糖脂代谢与肿瘤之间存在一定的相关性。糖脂代谢可以通过多种途径促进肿瘤的进展，相关基因的表达也直接或间接地影响肿瘤的代谢、转移、侵袭和凋亡。由于异常糖脂代谢的靶向药物递送系统在肿瘤治疗中的准确性和高效性，针对其设计的靶向药物已经有了大量的研究。此外，基因突变已成为肿瘤发生的一个重要因素。为此，将针对特定表达基因设计的药物转染到靶细胞中，以表达或沉默相应的蛋白质的基因治疗已经问世。用于实现相应治疗目的的靶向基因药物载体也在迅速发展。将与糖脂代谢相关的基因作为靶点，构建相应的基因药物载体，影响和干扰相关基因的表达，从而阻断肿瘤的发生过程，抑制肿瘤的生长。设计针对肿瘤内与糖脂代谢相关的基因的药物被认为是治疗肿瘤疾病的一种很有前途的策略。本文总结了近年来用于治疗肿瘤异常糖脂代谢的化学药物/基因药物传递系统及相应的方法，为开发糖脂代谢相关治疗方法提供了理论依据。
